Sun Pharmaceutical Industries Ltd. on Thursday said it has received final approval from the U.S. health regulator for Mesalamine extended-release capsules, used to treat bowel disease, in the American market.
The company has received approval from the U.S. Food and Drug Administration for the product, a generic version of Pentasa extended release capsules (500 mg), the Mumbai-based drug major said in a statement.
As per March 2022 IQVIA Health data, Pentasa had annualised sales of around $213 million in the U.S. market.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
